Experimental Unapproved Treatments for COVID-19
- Experimental Unapproved Treatments for COVID-19
- Accession Number
Drugs that are being investigated as potential treatment options for coronavirus disease 2019 (COVID-19). Towards the end of 2019, a large number of patients in Wuhan, China presented with atypical pneumonia. The cause of this disease was identified as 2019 novel coronavirus (2019-nCoV), which was renamed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) on February 11, 2020 by the World Health Organization (WHO).
Drug Drug Description Remdesivir A nucleoside analog used to treat RNA virus infections including COVID-19. Ritonavir An HIV protease inhibitor used in combination with other antivirals in the treatment of HIV infection. Chloroquine An antimalarial drug used to treat susceptible infections with P. vivax, P. malariae, P. ovale, and P. falciparum. It is also used for second line treatment for rheumatoid arthritis. Darunavir A HIV protease inhibitor used in the treatment of human immunodeficiency virus (HIV) infection in patients with history of prior antiretroviral therapies. Lopinavir An HIV-1 protease inhibitor used in combination with ritonavir to treat human immunodeficiency virus (HIV) infection. Galidesivir Galidesivir is an adenosine analogue that has been investigated for use against Zaire Ebolavirus. In animal studies, galidesivir was effective in increasing the survival rates from infections caused by various... Favipiravir An antiviral used to manage influenza, and that has the potential to target other viral infections. Umifenovir A dual direct-acting antiviral/host-targeting agent used in the treatment and prophylaxis of influenza and other respiratory viruses. Human interferon beta A polypeptide drug used in the treatment of relapsing forms of Multiple Sclerosis (MS). Triazavirin An antiviral used to treat several strains of influenza. TMC-310911 TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available darunavir. It is being investigated for use in HIV-1 infections.... mRNA-1273 mRNA-1273 is a vaccine developed by Moderna that is currently undergoing investigation for the prophylaxis of SARS-CoV-2 infection. It is a novel mRNA-based vaccine, encapsulated in a lipid nanoparticle, that... Ad5-nCoV Ad5-nCoV is a recombinant adenovirus type-5 vector (Ad5) vaccine currently being investigated for prophylaxis against SARS-CoV-2.[L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute... AZD1222 AZD1222 (previously known as ChAdOx1 nCoV-19) is a vaccine currently being investigated for prophylaxis against SARS-CoV-2. The ChAdOx1 viral vector was developed at the University of Oxford and has been... Fingolimod A sphingosine 1-phosphate receptor modulator used to treat patients with the relapsing-remitting form of multiple sclerosis (MS) and studied to manage lung complications of COVID-19. Methylprednisolone A corticosteroid used to treat inflammation or immune reactions across a variety of organ systems, endocrine conditions, and neoplastic diseases. Bevacizumab A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer. Leronlimab A humanized monoclonal antibody being investigated Azithromycin A macrolide antibiotic used to treat a variety of bacterial infections. N4-Hydroxycytidine A cytidine analog being investigated to treat COVID-19. EIDD-2801 An orally bioavailable isopropylester cytidine analog being investigated to treat COVID-19. Elbasvir An antiviral and NS5A inhibitor used to treat hepatitis C infections. Tocilizumab An interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA). GS-441524 An experimental nucleoside analog antiviral investigated for its use in the treatment of Ebola and SARS-CoV-2 infections. Tridecactide An investigational modified alpha melanocyte stimulating hormone being studied for the treatment of COVID-19. Metenkefalin An investigational endogenous opioid being studied for the treatment of COVID-19. Vazegepant Vazegepant is an antagonist of the calcitonin gene-related peptide (CGRP) receptor currently in phase 3 trials in an intranasal formulation for the treatment of migraine. If FDA approved, it will... Ibuprofen An NSAID and non-selective COX inhibitor used to treat mild-moderate pain, fever, and inflammation. Anti-SARS-CoV-2 REGN-COV2 Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. This drug is a combination of... Dexamethasone A glucocorticoid available in various modes of administration that is used for the treatment of various inflammatory conditions, including bronchial asthma, as well as endocrine and rheumatic disorders. COVID-19 convalescent plasma COVID-19 convalescent plasma is plasma collected from patients who have acquired and subsequently recovered from COVID-19 and which contains antibodies against the causative agent SARS-CoV-2. This investigational COVID-19 treatment is... INO-4800 INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. Early in vitro studies using HEK-293T cells demonstrated that... BNT162b1 SARS-CoV-2 Vaccine BNT162b1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding... BNT162b2 SARS-CoV-2 Vaccine BNT162b2 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162b2 is a nucleoside modified mRNA (modRNA) vaccine encoding... BNT162a1 SARS-CoV-2 Vaccine BNT162a1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162a1 is a uridine mRNA (uRNA) vaccine formulated in... BNT162c2 SARS-CoV-2 Vaccine BNT162c2 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in... Colchicine An alkaloid used in the symptomatic relief of pain in attacks of gout and to treat the inflammatory symptoms of Familial Mediterranean Fever (FMF). Bamlanivimab Bamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples taken in the United States from a patient who recovered... AZD7442 AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. It was developed by AstraZeneca with the... GC-376 free acid GC-376 is a 3C-like protease (3CLpro or Mpro) inhibitor that stops the cleavage and activation of functional viral proteins required for replication and transcription in host cells . The compound... GC-373 GC-373 is a peptide aldehyde which is metabolized from the bisulfide adduct, GC-376 free acid[A219031,A219036]. It is an inhibitor of Mpro (otherwise known as 3CLpro), a viral encoded protease that... Ifenprodil N-methyl-D-aspartate (NMDA) receptors (NMDARs) are members of the ionotropic glutamate receptor family, with key roles in brain development and neurological function.[A220118, A220128] NMDARs are heterotetramers that typically involve a dimer... Abivertinib Abivertinib is a tyrosine kinase inhibitor targeted against mutant forms of both human epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK). It has been investigated for use in... Etesevimab Etesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain.[L16651,L16661]
- Drugs & Drug Targets